• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Chronic Disease

Acamprosate found to be one of few effective and tolerable interventions for alcohol dependence

byDavy LauandAlex Chan
December 4, 2020
in Chronic Disease, Psychiatry
Reading Time: 3 mins read
Share on FacebookShare on TwitterShare on LinkedIn

1. Out of 43 interventions, acamprosate was the only intervention associated with greater likelihood of alcohol abstinence compared to placebo.

2. Acomprosate, naltrexone, and acomprosate-naltrexone were associated with lower dropout rates compared to placebo.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Excessive alcohol consumption has long been associated with a number of medical conditions, in particular liver disease. However, support and treatment for individuals with alcohol dependence are not always accessible: In the United Kingdom for example, only 1 in 4 with alcohol dependence seek treatment, and 82% of those don’t receive the specialist treatment they need. Therefore, supporting and treating alcohol dependence in a primary care setting is a potential consideration. The current study is a systematic review and meta-analysis, aiming to determine which interventions suitable for a primary care setting are most effective for alcohol abstinence. The findings showed that out of 43 pharmacological, psychosocial, and combined interventions, acamprosate was the sole intervention with sufficient evidence correlating it to a greater likelihood of alcohol abstinence for up to 12 months. As well, the only interventions with lower dropout rates were acamprosate, naltrexone, and acamprosate-naltrexone. The central strength of this study was the analysis of randomized controlled trials only, which compared interventions to a placebo or other control. The main weaknesses of this study were that most of the trials were small, single trials, with little high-quality data supporting interventions that would be suitable for primary care. Furthermore, few studies were conducted on combined pharmacological and/or psychosocial interventions.

Click here to read the study in the BMJ (British Medical Journal)

Relevant Reading: Therapeutic interventions for alcohol dependence in non-inpatient settings: a systematic review and network meta-analysis (protocol)

RELATED REPORTS

#VisualAbstract: Acamprosate found an effective and tolerable interventions for alcohol dependence

Patient Basics: Alcohol Use Disorder (Alcohol Dependence, Alcoholism)

In-Depth [systematic review and meta-analysis]: This study analyzed 64 randomized controlled trials on interventions for adults with alcohol dependency who had undergone detoxification during the study or within 4 weeks prior. Outcomes measured include continuation of abstinence over the study period, to assess the intervention’s effectiveness, and the drop-out rate, to gauge the tolerability of the intervention. The results showed with moderate confidence that acamprosate was associated with increased odds of abstinence for up to 12 months, compared to placebo (odds ratio 1.86, 95% CI 1.49-2.33). A few interventions were also associated with increased odds, but with weak confidence, such as topiramate, sodium oxybate, and quietapine. No psychosocial interventions correlated to greater abstinence. In terms of drop-out rates, the interventions with reduced dropout rates compared to placebo (with moderate confidence) were acamprosate (OR 0.73, 95% CI 0.62-0.86), naltrexone (OR 0.70, 95% CI 0.50-0.98), and acamprosate-naltrexone combined (OR 0.30, 95% CI 0.13-0.67). Therefore, acamprosate was the only intervention in this systematic review and meta-analysis found to be effective and tolerable for abstinence in adult alcohol-dependence patients, with the potential for usage in primary care settings.

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Alcohol Dependence
Previous Post

Neuraxial anesthesia associated with decreased 30-day all-cause mortality for patients undergoing lower limb revascularization

Next Post

Laparoscopic sigmoid resection for recurrent diverticulitis associated with higher quality of life scores

RelatedReports

Sotagliflozin reduces hospitalizations and urgent visits for patients with diabetes and worsening heart failure
StudyGraphics

#VisualAbstract: Acamprosate found an effective and tolerable interventions for alcohol dependence

December 10, 2020
Alcoholism recovery collage: a calm man in his thirties, a circle of empty chairs, a glass of water and a small lantern
Health A to Z

Patient Basics: Alcohol Use Disorder (Alcohol Dependence, Alcoholism)

October 30, 2026
Next Post

Laparoscopic sigmoid resection for recurrent diverticulitis associated with higher quality of life scores

#VisualAbstract B-Cell Targeted Therapies in CANOMAD Syndrome

#VisualAbstract B-Cell Targeted Therapies in CANOMAD Syndrome

Decline in MMR vaccination rate during the COVID-19 pandemic

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Large genetic association study identifies additional Alzheimer disease risk loci and candidate pathways
  • Pelacarsen lowers lipoprotein(a) but does not reduce major cardiovascular events in patients with established cardiovascular disease
  • Durvalumab plus enfortumab vedotin was approved for perioperative treatment of muscle-invasive bladder cancer
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.